{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-096483","form_type":"8-K","ticker":"REPL","cik":"0001737953","company_name":"Replimune Group, Inc.","filed_at":"2026-08-14T12:10:29+00:00","discovered_at":"2026-08-14T12:15:03.012671+00:00","generated_at":"2026-08-14T12:15:11.634202+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":1.0,"calibrated_materiality_score":1.0,"confidence":"high","headline":"Replimune wins FDA accelerated approval for TUDRIQEV melanoma combo; Q1 net loss $69.8M","bullets":["FDA granted accelerated approval for TUDRIQEV (RP1) plus nivolumab in advanced melanoma; launch within 60 days.","Completed $150M financing; net proceeds $141M; cash and equivalents $195.3M as of June 30, 2026.","Q1 FY2027 net loss $69.8M vs $86.7M; R&D $49.3M, SG&A $19.0M.","Michelle DiNapoli appointed Chief Commercial Officer, effective Aug 18, 2026; ex-Deciphera.","IGNYTE-3 confirmatory trial readout expected 2030; REVEAL Phase 2/3 for RP2 enrolling."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-096483","json":"https://secwatch.observer/filing/0001104659-26-096483.json","markdown":"https://secwatch.observer/filing/0001104659-26-096483.md","text":"https://secwatch.observer/filing/0001104659-26-096483.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1737953/000110465926096483/0001104659-26-096483-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1737953/000110465926096483/tm2623208d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-14T12:15:11.634202+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}